Dr. Rafael Rosell
Dr. Rafael Rosell
Dr. Rosell has specialised in oncology since 1982. Since then, he has worked tirelessly on researching a cure for cancer. Dr. Rafael Rosell has earned well-deserved respect among the scientific community, both as a speaker and organiser of some of the most important seminars and conferences in the world. He pays special attention to the field of translational oncology of large-cell lung cancer. As Head of the Dr. Rosell Oncology Institute, he works closely with the Oncology Laboratory to provide molecular diagnoses and personalised treatments depending on the genetic characteristics of each patient. In 2013, The Lancet named Dr. Rosell as the European leader in lung cancer.
- Director of the Cancer Biology and Personalised Medicine Programme, Catalonian Institute of Oncology, Germans Trias i Pujol Hospital, Badalona (Barcelona).
- Founder and Scientific Director of Pangaea Oncology S.A.
- Founder and President of the Molecular Oncology Research Foundation (MORe).
- Founder and Projects and International Relations Director of the Spanish Lung Cancer Group (GECP).
- Founding Board Member of the European Thoracic Oncology Platform (ETOP).
- He has given over 800 presentations at conference, as well as organising some of the most important seminars and conferences in the world, for example, the International Association for the Study of Lung Cancer (IASLC), the European Medical Oncology Society (ESMO) and the American Society of Clinical Oncology (ASCO).
- International Association for the Study of Lung Cancer (IASLC); Chair, 2005 World Conference on Lung Cancer.
- European Society for Medical Oncology (ESMO); Member, Scientific Program Sub-Committee (non-small-cell lung cancer, metastatic) for the ESMO annual congress.
- European Organization for Research and Treatment of Cancer (EORTC).
- American Society of Clinical Oncology (ASCO); Member of Scientific Program Committee 2002-2004.
- Spanish Lung Cancer Group (President, 1991-2014).
- Dr. Rosell has written over 600 scientific articles in renowned medical journals, such as the New England Journal of Medicine, Clinical Cancer Research, Oncogene, The Lancet, The Lancet Oncology, Annals of Oncology and many more. He is also a member of editorial committees for various prestigious journals and has won many awards in acknowledgement of his extensive scientific work.
- Special attention must be given to his contributions to the field of translational oncology in non-small-cell lung cancer, as the first to prove the superiority of Tarceva® in terms of progression-free survival in European patients with EGFR gene mutations who were treated in the EURTAC trial.
No. of patents (in which he participated):
- Title: Molecular Biomarkers for Predicting Response to Tyrosine-kinase Inhibitors in Lung Cancer.
- Title: Method for the detection o EGFR mutations in blood samples.
- Title: Molecular biomarkers for predicting response to Tyrosine-kinase Inhibitors in lung cancer.
- Title: Methods and reagents for predicting clinical outcome and customizing chemotherapy in lung cancer patients.
- Title: BRCA-1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy.
- Title: BRCA1 mRNA expression predicts survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy.
- 1982: Memorial Sloan-Kettering Cancer Centre, New York, under the tutorship of Dr. R. Gralla, Dept. of Medicine (Developmental Chemotherapy).